Filing summary
Identity discrepancy: The request identifies Canton Strategic Holdings, Inc., but the supplied Form 10-Q is for Hillstream BioPharma, Inc. (Nasdaq: HILS). This summary reflects the filing text provided, not Canton Strategic Holdings.
Business context and reporting period
Hillstream is a preclinical biotechnology company developing immuno-oncology candidates targeting HER2, HER3 and PD-1. This unaudited filing covers the quarter and six months ended June 30, 2023; it was signed August 11, 2023. The company reported no revenue for the three-month periods compared.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | Not clearly stated for six months | Not clearly stated for six months |
| Research and development | $1.03 million | $0.46 million | $2.08 million | $0.76 million |
| General and administrative | $1.33 million | $1.18 million | $3.00 million | $2.22 million |
| Total operating expenses | $2.36 million | $1.64 million | $5.08 million | $2.99 million |
| Net loss | $2.34 million | $1.64 million | $5.03 million | $4.58 million |
| Operating cash used | Not provided by quarter | $4.98 million | $4.12 million |
- Q2 loss per share was $0.16 versus $0.14; six-month loss per share was $0.38 versus $0.41.
- At June 30, cash and total current assets were $3.90 million; current liabilities were $1.53 million; stockholders’ equity was $3.07 million. The balance sheet lists no noncurrent assets or liabilities.
- Cash declined $2.61 million in the first half. Financing activities provided $2.37 million, including approximately $2.26 million of net common-stock proceeds; the May offering yielded approximately $2.1 million net.
- Current liabilities included a $322,046 insurance-premium financing liability, due in October 2023. No other outstanding debt balance is shown on the June 30 balance sheet.
- Margins are not meaningful because the company reported no revenue.
Changes versus prior period
Q2 operating expenses rose $727,742 year over year, mainly from increased preclinical R&D activity; net loss widened by $700,060. For the first half, operating expenses increased $2.09 million, while net loss increased by a smaller $445,944. The comparison benefited from $1.59 million of debt-discount interest expense in first-half 2022, largely associated with the conversion of related-party convertible notes at the IPO. First-half operating cash use increased by $859,371. The May 2023 offering issued 5.3 million shares at $0.50 each, increasing outstanding shares and providing additional cash.
Outlook, risks and unusual items
- Management states it needs substantial additional funding and that recurring operating losses and negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern for at least one year after the financial statements were issued. Additional financing is not assured; a shortfall could delay or end development activities.
- Management expected HSB-3215, HSB-0059 and HSB-1940 to enter IND-enabling studies in 2024. Timelines and costs depend on research progress, trial design and enrollment, regulatory requirements, manufacturing and available funding.
- After quarter-end, Hillstream signed a collaboration and license agreement with Applied Biomedical Science Institute (July 5). Consideration includes 627,667 shares issued for a stated $250,000 value, potential milestone payments of up to $8.25 million, and royalties and other payments under specified conditions.
- On July 6 and July 11, the company entered into amended CEO and new COO employment agreements. The agreements provide annual base salaries of $500,000 and $400,000, respectively, plus eligibility for bonuses and other compensation.
- Nasdaq notified the company on June 12 that its bid price had been below $1 for 30 consecutive business days. The stated initial compliance deadline was December 11, 2023; delisting could impair trading liquidity and access to capital.
- Management concluded disclosure controls were not effective as of June 30, citing weaknesses in segregation of duties and technical accounting review. Remediation efforts include quarterly contract review and using third-party accounting experts.
- The filing also cites COVID-19-related uncertainty and says the pandemic previously delayed the start of IND-enabling studies by more than a year. The company reported no legal proceedings known to have a material adverse effect.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Hillstream BioPharma, not Canton Strategic Holdings.
- Review cash runway, expected burn and financing needs against the company’s going-concern warning and current liabilities.
- Track clinical and IND-enabling milestones, funding availability, and the terms and obligations of the ABSI and Minotaur/Taurus arrangements.
- Check subsequent filings for Nasdaq bid-price compliance, any reverse stock split, and further share issuance or dilution.
- Monitor remediation of the disclosed control weaknesses and any changes to executive compensation arrangements.